Senores Pharmaceuticals logo

Senores Pharmaceuticals

SENORES NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹6,660 Cr
Volatility
Moderate
P/E Ratio
53.49
EBITDA
₹168 Cr
Return on Equity
7.18%
Debt to Equity
0.37
Book Value
₹202.72
52W High
₹1,599
52W Low
₹662.45

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

6
  • Stock is trading at 7.24 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 13.9% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 187 days.
  • Working capital days have increased from 67.9 days to 132 days

Growth Rate

Revenue Growth
51.53% lower than 3Y
Net Income Growth
139% level than 3Y
Cash Flow Change
-78.68%
ROE
-49.15% lower than 3Y
ROCE
1.63% higher than 3Y
EBITDA Margin (Avg.)
-5.13% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Senores Pharmaceuticals trades at a market cap of ₹6,358 Cr with a PE of 52.3x and has delivered exceptional top-line growth of 162% CAGR over 3 years, but carries concerns around working capital efficiency with debtor days at 187 and no dividend payouts despite consistent profitability.

Bull Case 7
  • Compounded sales growth of 162% CAGR over 3 years indicates rapid revenue scale-up in the pharmaceutical space
  • TTM sales growth of 59% demonstrates continued strong momentum even on a larger base
  • Compounded profit growth of 139% CAGR over 3 years outpaces many pharma peers significantly
  • TTM profit growth of 97% shows accelerating bottom-line expansion year-over-year
  • Stock has delivered 144% returns over 1 year reflecting strong market confidence in the business trajectory
  • Company is expected to deliver a good upcoming quarter based on operational momentum
  • Consistent ROE of 13-14% over the last 3 years indicates stable profitability despite rapid growth phase
Bear Case 8
  • Debtor days at 187 days is extremely high, indicating potential collection challenges or channel-stuffing risk
  • Working capital days have deteriorated sharply from 67.9 days to 132 days, straining cash flows
  • PE ratio of 52.3x is expensive relative to broader pharma sector averages of 25-35x, leaving limited margin of safety
  • Price-to-book of 6.81x is elevated for a company with ROE of only 13.9%, implying premium valuation not fully justified by returns
  • Zero dividend yield despite reporting repeated profits suggests cash is being retained without clear capital allocation policy
  • ROE of 13.9% over 3 years is below the 15-20% threshold typically expected for quality pharma compounders
  • Possible capitalization of interest costs may be flattering reported profitability relative to true operating performance
  • Limited long-term track record with no available 5-year or 10-year growth data makes durability of growth difficult to assess

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Headwinds 3
  • IPO proceeds utilisation change sought Jul 4

    Company seeks shareholder approval to vary utilisation of ₹650.16 million in unutilised IPO proceeds, raising questions about original capital allocation plans.

  • Large related party transactions Jul 4

    Seeking approval for material related party transactions aggregating ₹754 crore and enhanced limits for loans/guarantees under Sections 185 and 186.

  • Company Secretary relieved Jun 10

    CS Vinay Kumar Mishra relieved from duties effective June 10, 2026, with MD and CFO now handling disclosures directly.

Neutral 3
  • Postal ballot voting opens Jul 4

    Voting on IPO proceeds variation and RPT approvals runs from July 5 to August 3, 2026.

  • Analyst meet in Ahmedabad Jul 1

    Group meeting for analysts and investors scheduled for July 7, 2026, in Ahmedabad using publicly available information.

  • Virtual investor conference Jun 9

    Virtual investor conference hosted by Choice Broking held on June 12, 2026, relying on publicly available information.

TL;DR: Senores Pharmaceuticals is in a governance-heavy phase with no operational positives reported. The proposed variation of ₹650.16 million in IPO proceeds and ₹754 crore in related party transactions warrant investor scrutiny on capital discipline. The departure of the Company Secretary adds mild uncertainty. The near-term outlook depends on shareholder approval outcomes by August 3 and clarity on how redirected funds will be deployed.

Quarterly Results

Particulars Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
79
102
80
101
103
114
138
162
171
175
180
Expenses
64
80
59
77
77
95
104
112
121
128
126
Operating Profit
15
22
21
23
26
19
34
50
50
47
54
OPM %
19%
22%
27%
23%
25%
17%
25%
31%
29%
27%
30%
Other Income
1
2
0
2
5
12
3
5
7
18
3
Interest
2
3
5
5
6
5
5
6
5
8
7
Depreciation
3
4
4
4
4
5
6
8
8
9
10
PBT
10
18
13
16
20
21
26
41
45
47
39
Tax %
31%
19%
19%
18%
20%
13%
20%
26%
25%
23%
23%
Net Profit
7
14
11
13
16
18
21
30
34
37
30
EPS in Rs
2.37
5.23
3.23
3.86
3.73
3.87
4.28
7.03
6.87
6.86
6.67
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
14
35
215
398
633
688
Expenses
12
23
173
309
464
487
Operating Profit
2
13
42
90
168
201
OPM %
14%
36%
19%
23%
27%
29%
Other Income
0
4
3
19
47
33
Interest
1
2
9
22
25
27
Depreciation
1
2
10
17
31
35
PBT
1
12
25
71
159
172
Tax %
13%
32%
-31%
17%
24%
—
Net Profit
1
8
33
58
122
131
EPS in Rs
1.01
8.59
10.31
12.72
25.05
27.43
Div. Payout %
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
10
31
46
46
Reserves
28
36
174
740
888
Borrowings
15
63
258
315
342
Other Liabilities
8
23
160
126
328
Total Liabilities
59
131
622
1,227
1,604
Fixed Assets
7
27
235
301
755
CWIP
8
34
97
172
17
Investments
15
16
0
0
4
Other Assets
29
53
289
754
827
Total Assets
59
131
622
1,227
1,604
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-10
-1
-26
-46
62
Investing
-24
-48
-54
-429
-121
Financing
36
46
87
573
-1
Net Cash Flow
2
-3
8
98
-60
Free Cash Flow
-21
-48
-78
-203
-203
CFO/OP
-526
3
-56
-41
45
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
506
228
191
114
187
Inventory Days
135
89
184
232
130
Days Payable
324
388
556
275
340
Cash Conversion Cycle
317
-71
-182
70
-24
Working Capital Days
359
-7
-16
88
132
ROCE %
—
18%
12%
11%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Senores Pharmaceuticals insights

56 extracted metrics + investor summaries across FY22–FY27.

Log in — free

Shareholding Pattern

FIIs6.62%Promot.45.82%Others8.55%DIIs9.77%Public29.25%As ofJun 2026
2.81% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about Senores Pharmaceuticals

What does Senores Pharmaceuticals Ltd do?
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
Where is Senores Pharmaceuticals Ltd (SENORES) listed?
Senores Pharmaceuticals Ltd trades as SENORES on the NSE and under code 544319 on the BSE.
Which sector does Senores Pharmaceuticals Ltd belong to?
Senores Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a market capitalisation of ₹6,660 Cr, which places it in the Mid Cap band.
What is the PE ratio of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd trades at a PE ratio of 53.49, against a book value of ₹202.72 per share.
What is the 52-week high and low of Senores Pharmaceuticals Ltd?
Over the last 52 weeks Senores Pharmaceuticals Ltd has traded between ₹662.45 and ₹1,599.
What is the Return on Equity (ROE) of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd reported a return on equity of 7.18%. Its debt-to-equity ratio is 0.37.

Company Information

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Website senorespharma.com
Listed 2024-12-30
Face Value ₹ 10
Issued Size 4,60,53,588

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SENORES.md for Senores Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List